Navigation Links
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
Date:11/8/2010

h fistulizing CD.  
  • Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active UC who have had an inadequate response to conventional therapy.
  • Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in patients with PsA.  
  • Treatment of adult patients with chronic severe plaque PsO who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.

  • REMICADE is unique among available anti-TNF biologic therapies. It is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. REMICADE is a two-hour infusion administered every 4 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE patients may require as few as six treatments each year as maintenance therapy.

    IMPORTANT SAFETY INFORMATION FOR REMICADE

    Only your doctor can recommend a course of treatment after checking your health condition. REMICADE (infliximab) can cause serious side effects such as lowering your ability to fight infections. There are reports of serious infections caused by viruses, fungi or bacteria that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Your doctor should monitor you closely for signs and symptoms of TB during treatment with REMICADE.

    Unusual cancers have been reported in children and teenage patients taking TNF-blocker medicines. A rare form of fatal lymphoma has occurred mostly in teenage or young adult males with Crohn's disease or ulcerative colitis who were taking REMICADE and azathioprine or 6-mercaptopurine. For
    '/>"/>

    SOURCE Centocor Ortho Biotech, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
    2. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
    3. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
    4. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
    5. SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
    6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
    10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... August 29, 2014 According ... Market by Extraction type (SFE, Cold Pressed, Organic ... Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - Global ... defines and segments the Amaranth Seed Oil Market ... size in terms of value. The Amaranth Seed ...
    (Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
    (Date:8/29/2014)... -- In part four of a blog series ... a strategic asset, Mary Baxter, MBA, RPh ., ... Innovation Delivery Solutions business, discusses how expanding patient access ... patients. "Every hospital pharmacist knows that filling ... in a value-based healthcare world," Baxter says. "For the ...
    Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4
    ... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company ... Tom Wegman , will present at the upcoming Jefferies & Company 2010 ... 2:30pm EDT . , ... A live webcast of the presentation can be accessed under "Calendar ...
    ... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) announced today ... Thursday, June 10, 2010 at The Grand Hyatt Hotel in ... Executive Officer, will discuss the Company,s business strategy and historical financial performance at ... , , ...
    Cached Medicine Technology:BioSpecifics Technologies Corp. to Present at Jefferies & Company 2010 Global Life Sciences Conference 2BioSpecifics Technologies Corp. to Present at Jefferies & Company 2010 Global Life Sciences Conference 3Questcor to Present at the Jefferies 2010 Global Life Sciences Conference 2
    (Date:9/1/2014)... 01, 2014 Ontraport , one ... that was developed to automate the small intricacies of ... of Shane Michaels, prompting an investigative review. , ... duty of managing all of the small details involved ... overwhelming,” reports Michaels. “That’s why Ontraport has become so ...
    (Date:9/1/2014)... 2014 AttorneyOne.com, a recognized authority on ... information from the FDA on DePuy Synthes Craniomaxillofacial ... on August 28, that specific lots of DePuy Synthes ... as the device may reverse directions after surgery. ... Distraction System is an implant used to lengthen and/or ...
    (Date:9/1/2014)... Nevada (PRWEB) September 01, 2014 Beginning ... to over 3,000 medical professionals and 10,000 consumers for ... is a 5-day gathering of the nation’s top medical ... associated diseases or conditions. The week-long event contains more ... evidence-based scientific instruction available in the pain management field. ...
    (Date:8/31/2014)... 31, 2014 An analysis of 32 ... has revealed a link between lower levels of Vitamin ... in the August 2014 issue of American ... main form of Vitamin D found in blood. ... 25-Hydroxyvitamin D lower than 9 nanograms/milliliter (ng/mL) were twice ...
    (Date:8/31/2014)... (PRWEB) August 31, 2014 The FDA ... Nutrition Facts label. If adopted, the proposed changes would ... addition of “added sugars” on the label, and a ... to keep “added sugars” off the label. NutriGold fully ... consumers make healthier food choices. “After 20 years, it's ...
    Breaking Medicine News(10 mins):Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 3Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 4
    ... of a new use for magnetic levitation, or "maglev," ... trains to float above the tracks. In ACS, bi-weekly ... describe putting maglev to use in an inexpensive sensor ... Whitesides and colleagues note that measurements of a substance,s ...
    ... in Spanish . Ensuring the optimum ... in prostate cancer treatment manages to control the illness in ... research undertaken at the University Hospital of Navarre and published ... the American Society of Brachytherapy. As is known, brachytherapy ...
    ... (June 23, 2010) Children who experience maltreatment ... likely to experience frequent headaches, including chronic migraine, as ... Headache Society,s 52nd Annual Scientific Meeting in Los Angeles ... Experiences (ACE) Study of 17,337 adult members of the ...
    ... Some 19 percent of soldiers returning from Iraq have ... While prevalence of migraine among the U.S. military ... quality in soldiers with chronic headaches including post-traumatic headache ... Army Medical Center in Tacoma, WA presenting at American ...
    ... having the most expensive health care system, the United ... countriesAustralia, Canada, Germany, the Netherlands, New Zealand, and the ... areas: quality, efficiency, access to care, equity and the ... a new Commonwealth Fund report. While there is room ...
    ... research professor in the department of physics at NJIT, ... Research Council (NRC) of the National Academies ( www.nationalacademies.org ... vehicles in the aftermath of Toyota,s large recalls. The ... and July 1, 2010 in Washington, DC, includes notable ...
    Cached Medicine News:Health News:Optimizing brachytherapy dose on the same day as the implant can control prostate cancer 2Health News:US ranks last among 7 countries on health system performance 2Health News:US ranks last among 7 countries on health system performance 3Health News:NJIT professor heads panel studying sudden car acceleration 2
    The modular, high-end stereomicroscope; meets even the most critical demands in research and quality control provides high-contrast images with excellent depth of field and color fidelity...
    6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
    Fixed Versatility - With a diverse selection of body tubes, stands, lighting techniques and Nikon's world-renowned optics, this modular microscope can be configured to fit nearly any application....
    ... designed to have the following properties and ... sections, cell cultures, specimens with aqueous embedding ... cover glass thickness (0.14...0.18 mm) and temperatures ... correction collar can also be used for ...
    Medicine Products: